Filipīnas - angļu - FDA (Food And Drug Administration)

euro-care products philippines; distributor: primus medicus distributor, inc - hydrocortisone (as sodium succinate) - powder for injection (im/iv) - 100mg

Austrālija - angļu - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zagro australia pty ltd - levamisole hydrochloride; oxyclozanide - oral solution/suspension - levamisole hydrochloride anthelmintic active 75.0 g/l; oxyclozanide anthelmintic active 150.0 g/l - parasiticides

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

auditdata pty ltd - 45241 - audiometric measuring instrument - the primus fitting unit is a module based audiometric testing platform for real-ear-measurements to verify hearing aid performance when the hearing aid is worn on the patient's ear. the hardware is connected to a computer and is controlled by a suite of dedicated software loaded on to the same computer.

Singapūra - angļu - HSA (Health Sciences Authority)

draeger singapore pte ltd - anaesthesiology - the drager primus anaesthetic workstation is for adults, children and neonates, providing automatic and manual ventilation, as well as spontaneous breathing.

Singapūra - angļu - HSA (Health Sciences Authority)

swifthac engineering pte. ltd. - dental - kavo primus® 1058 equipment system is a dental treatment unit. it aids the dental application in the mouth of patient by supplying air, water or spray.

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

primus pharmaceuticals, inc. - clobetasol propionate (unii: 779619577m) (clobetasol - unii:adn79d536h) - impoyz cream 0.025% is indicated for the treatment of moderate to severe plaque psoriasis in patients 18 years of age and older. none. risk summary there are no available data on impoyz cream in pregnant women to inform a drug-associated risk for adverse development outcomes. published data report a significantly increased risk of low birthweight with the use of greater than 300 grams of potent or very potent topical corticosteroids during a pregnancy. advise pregnant women of the potential risk to a fetus and to use impoyz cream on the smallest area of skin and for the shortest duration possible (see data ). in animal reproduction studies, increased malformations, such as cleft palate and skeletal abnormalities, were observed after subcutaneous administration of clobetasol propionate to pregnant mice and rabbits. no comparisons of animal exposure with human exposure are provided due to minimal systemic exposure noted after topical administration of impoyz cream [see clinical pharmacology (12.3) ]. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk or birth defect loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. data human data multiple observational studies found no significant associations between maternal use of topical corticosteroids of any potency and congenital malformations, preterm delivery, or fetal mortality. however, when the dispensed amount of potent or very potent topical corticosteroid exceeded 300 g during the entire pregnancy, use was associated with an increase in low birth weight infants [adjusted rr, 7.74 (95% ci, 1.49-40.11)]. in addition, a small cohort study, in which 28 sub-saharan women using potent topical corticosteroids (27/28 used clobetasol propionate 0.05%) for skin lightening during pregnancy, noted a higher incidence of low birth weight infants in the exposed group. the majority of exposed subjects treated large areas of the body [a mean quantity of 60 g/month (range, 12-170g)] over long periods of time. animal data in an embryofetal development study in mice, subcutaneous administration of clobetasol propionate resulted in fetotoxicity at the highest dose tested ( 1mg/kg) and malformations at the lowest dose tested (0.03 mg/kg). malformations seen included cleft palate and skeletal abnormalities. in an embryofetal development study in rabbits, subcutaneous administration of clobetasol propionate resulted in malformations at doses of 0.003 and 0.01 mg/kg. malformations seen included cleft palate, cranioschisis, and other skeletal abnormalities. risk summary there is no information regarding the presence of clobetasol propionate in breast milk or its effects on the breastfed infant or on milk production. systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. it is not known whether topical administration of clobetasol propionate could result in sufficient systemic absorption to produce detectable quantities in human milk. the developmental and health benefits of breastfeeding should be considered along with the other’s clinical need for impoyz cream and any potential adverse effects on the breastfed infant from impoyz cream or from the underlying maternal condition. clinical considerations to minimize potential exposure to the breastfed infant via breast milk, use impoyz cream on the smallest area of skin and for the shortest duration possible while breastfeeding. advise breastfeeding women not to apply impoyz cream directly to the nipple and areola to avoid direct infant exposure. the safety and effectiveness of impoyz cream in patients younger than 18 years of age have not been established; therefore, use in children younger than 18 years is not recommended. because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of systemic toxicity, including hpa axis suppression when treated with topical drugs [see warnings and precautions (5.1) ]. rare systemic toxicities such as cushing’s syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in pediatric patients, especially those with prolonged exposure to large doses of high potency topical corticosteroids. local adverse reactions including striae and skin atrophy have also been reported with use of topical corticosteroids in pediatric patients. avoid use of impoyz cream in the treatment of diaper dermatitis. clinical studies of impoyz cream did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience with topical corticosteroids has not identified differences in responses between the elderly and younger patients. patient information impoyz® (im-poise) (clobetasol propionate) cream, 0.025% important: impoyz cream is for use on the skin only. do not get impoyz cream near or in your eyes, mouth, or vagina. what is impoyz cream? impoyz cream is a prescription corticosteroid medicine used to treat moderate to severe plaque psoriasis in people 18 year of age and older. it is not known if impoyz cream is safe and effective in children under 18 years of age. impoyz cream is not recommended for use in children under 18 years of age. before using impoyz cream, tell your doctor about all of your medical conditions , including if you: - have thinning of the skin (atrophy) at the treatment site. - have a skin infection. you may need medicine to treat the skin infection before using impoyz cream. - have diabetes. - have adrenal gland problems. - plan to have surgery. - liver problems - are pregnant or plan to become pregnant. it is not known if impoyz cream will harm your unborn baby. if you use impoyz cream during pregnancy, use impoyz cream on the smallest area of skin and for the shortest time needed. - are breastfeeding or plan to breastfeed. it is not known if impoyz cream passes into breast milk. breastfeeding women should use impoyz cream on the smallest area of skin and for the shortest time needed while breastfeeding. do not apply impoyz cream directly to the nipple and areola to avoid contact with your baby. tell your doctor about all the medicines you take , including prescription and over-the-counter medicines, vitamins, and herbal supplements. especially tell your doctor if you take other corticosteroid medicines by mount or use other products on your skin that contain corticosteroids. do not use other product containing a corticosteroid medicine with impoyz cream without talking to your doctor first. how should i use impoyz cream? - use impoyz cream exactly as your doctor tells you to use it - your doctor should tell you how much impoyz cream to use and where to apply it. - apply a thin layer of impoyz cream to the affected skin areas 2 times each day and rub in gently and completely. - use impoyz cream for the shortest amount of time needed to treat your plaque psoriasis. tell your doctor if your skin condition is not getting better after 2 weeks for using impoyz. do not use impoyz cream for longer than 2 weeks in a row. - do not use impoyz cream on your face, scalp, underarms (armpits), groin, or areas where your skin may touch or rub together. - do not use impoyz cream if thinning of the skin atrophy is present at the treatment site. - do not bandage, cover, or wrap the treated skin area unless your doctor tells you to. - wash your hand after you apply impoyz cream. - see your doctor regularly to check your symptom and side effects while using impoyz cream. what are the possible side effects of impoyz cream? impoyz cream may cause serious side effects, including: - symptoms of a disorder where the adrenal gland does not make enough of certain hormones (adrenal insufficiency) during treatment or after stopping treatment with impoyz cream. your doctor may do blood tests to check for adrenal gland problems during treatment with impoyz cream. - cushing syndrome , a condition that can happen when your body is exposed to too much of the hormone cortisol. your doctor may do tests to check for this. - high blood sugar (hyperglycemia) or diabetes mellitus that has not been diagnosed can happened with treatment. your doctor may do tests to check for this. - skin reactions at the treated skin site. tell your doctor if you get any skin reactions or skin infections. - effects on growth and weight in children. the most common side effect of impoyz cream includes discoloration of the treated site. this is not the only possible side effect of impoyz cream. call your doctor for medical advice about side effects. you may report side effects to fda at 1-800-fda-1088. how should i store impoyz cream? - store impoyz cream between 68°f to 77°f (20°c to 25°c). - do not freeze. - throw away (discard) any unused impoyz cream after 2 weeks. keep impoyz cream and all medicines out of the reach of children. general information about the safe and effective use of impoyz cream. medicines are sometimes prescribed for purposes other than those listed in the patient information leaflet. do not use impoyz cream for a condition for which it was not prescribed. do not give impoyz cream to other people even if they have the same symptoms that you have. it may harm them. you can ask your pharmacist or doctor for information about impoyz cream that is written for health professionals. what are the ingredients in impoyz cream? active ingredients: clobetasol propionate inactive ingredients: butylated hydroxytoluene, cetostearyl alcohol, cyclomethicone, diethylene glycol monoethyl ether, glyceryl stearate and peg 100 stearate, isopropyl myristate, methyl paraben, propyl paraben, purified water and white wax. manufactured by dpt laboratories ltd. san antonio, tx 78215 for primus pharmaceuticals, inc. scottsdale az 85253                                                                                                                                                                                                                                                                                                                                            revised 04/2021 this patient information has been approved by the u.s. food and drug administration       issued 11/2017                                                        

Amerikas Savienotās Valstis - angļu - NLM (National Library of Medicine)

primus pharmaceuticals, inc. - genistein (unii: dh2m523p0h) (genistein - unii:dh2m523p0h), zinc glycinate citrate (unii: h3472pj7ya) (zinc cation - unii:13s1s8sf37), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41) - genistein 27 mg - each fosteum capsule contains 27 mg of genistein aglycone (genistein), derived from a natural source, for a total daily intake of 54 mg. in clinical trials, this level of intake has been shown to increase bone mineral density (bmd). genistein is chemically described as 4',5,7-trihydroxyisoflavone or 5,7-dihydroxy-3-(4-hydroxyphenyl)-4h-1-benzopyran-4-one. it is the aglycone form of the glucoside isoflavone molecule genistin. the empirical formula of genistein is c15 h10 o5 ; its molecular weight is 270.2. the structural formula is: each fosteum capsule contains 20 mg citrated zinc bisglycinate, a glycine amino acid chelate of zinc formed in the presence of citric acid that provides approximately 4 mg of elemental zinc per capsule. zinc is an essential mineral co-factor required by enzymes involved in bone metabolism and has important physiological functions in other tissues throughout the body. elemental zinc has also been shown to have synergistic effects with genistein on bone formation. this zinc bisglycin

Singapūra - angļu - HSA (Health Sciences Authority)

carl zeiss pte. ltd. - ophthalmology - the primus 200 is used for in-vivo viewing of axial cross-sections of anterior and posterior ocular structures and measurement of anterior and posterior ocular structures.

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

atos medical ab -

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

atos medical ab -